Cancer Radiotherapie最新文献

{"title":"Best practice in brachytherapy: 2025 update","authors":"Jean-Michel Hannoun-Lévi ,&nbsp;Sophie Renard ,&nbsp;Pascal Pommier ,&nbsp;Lucie Houdou ,&nbsp;Fabien Mignot ,&nbsp;Julien Charret ,&nbsp;Pierre Blanchard ,&nbsp;Cyrus Chargari ,&nbsp;Marjorie Ferré","doi":"10.1016/j.canrad.2025.104714","DOIUrl":"10.1016/j.canrad.2025.104714","url":null,"abstract":"<div><div>The RecoRad™ 2025 recommendations for best practice in brachytherapy procedures are updated based on the 2022 article. This new brachytherapy article took into account recent data published in the literature as well as international recommendations. The different brachytherapy steps are successively described from the treatment preparation (brachytherapy technique prescription; procedure and applicators, dedicated images for planification, dose distribution analysis and validation) to the end of the procedure as well as post-treatment surveillance.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104714"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for external radiotherapy and brachytherapy procedures: 4th edition","authors":"Igor Latorzeff ,&nbsp;Alizée Camps-Malea ,&nbsp;Véronique Vendrely ,&nbsp;David Azria ,&nbsp;Laure Parent ,&nbsp;Émilie Bayart ,&nbsp;Stéphane Supiot","doi":"10.1016/j.canrad.2025.104718","DOIUrl":"10.1016/j.canrad.2025.104718","url":null,"abstract":"<div><div>The purpose of the first three editions of the guidelines for external radiotherapy procedures (RecoRad™, published in 2008, 2016 and 2021 respectively), was to issue recommendations aimed at optimising, harmonising and standardising practices. The purpose of this fourth edition, follow the same plan and takes into account recent technological improvements along with findings from literature. Part one describes the daily use of general principles; part two describes every step of the process treatment for the main types of cancer. This new edition is also an opportunity to integrate new chapters.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104718"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for endometrial cancer: 2025 update","authors":"Cyrus Chargari ,&nbsp;Anne Ducassou ,&nbsp;Julie Leblanc ,&nbsp;François Lucia ,&nbsp;Adeline Petit ,&nbsp;Isabelle Flandin ,&nbsp;Abel Cordoba ,&nbsp;Caroline Lafond ,&nbsp;Sophie Renard ,&nbsp;Alexandre Escande","doi":"10.1016/j.canrad.2025.104752","DOIUrl":"10.1016/j.canrad.2025.104752","url":null,"abstract":"<div><div>The first intent upfront treatment of endometrial cancer is surgery. External radiotherapy and brachytherapy, however, are important tools in adjuvant setting, according to histopathological risk factors for locoregional recurrence or in the event of an inoperable tumour. We present the 2025 update of the recommendations of the Société française de radiothérapie oncologique (SFRO; French society of radiation oncology) on the indications and technical methods of performing radiotherapy and brachytherapy for endometrial cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104752"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy of breast cancer: 2025 update","authors":"Youssef Ghannam ,&nbsp;Romuald Le Scodan ,&nbsp;Sofia Rivera ,&nbsp;Youlia Kirova ,&nbsp;David Pasquier ,&nbsp;Christophe Hennequin ,&nbsp;Céline Bourgier ,&nbsp;Bruno Cutuli ,&nbsp;Agnès Richard-Tallet","doi":"10.1016/j.canrad.2025.104767","DOIUrl":"10.1016/j.canrad.2025.104767","url":null,"abstract":"<div><div>Adjuvant radiotherapy is a key component in the management of breast cancer. After breast-conserving surgery for invasive carcinoma, adjuvant irradiation is systematically recommended regardless of patient characteristics, as it reduces the risk of local recurrence and improves survival. A boost to the tumour bed is indicated for patients under 50<!--> <!-->years of age. Partial breast irradiation may be considered as an alternative to whole-breast irradiation, but only in carefully selected and fully informed patients. For ductal carcinoma in situ, postoperative irradiation is also systematically recommended after lumpectomy. After mastectomy, chest wall irradiation is indicated for pT4 tumours or in the presence of nodal involvement; it may be individualized for pT3 or pN1 tumours. When neoadjuvant chemotherapy precedes mastectomy, radiotherapy is recommended if the initial tumour was classified as T3–T4 or if clinical or radiological nodal involvement was present prior to chemotherapy, indication which can be questioned in the absence of lymph node involvement on the surgical specimen, depending on the tumour subtype. Axillary irradiation is indicated based on nodal dissection findings and may be considered in cases of sentinel node involvement without dissection. Supraclavicular and infraclavicular nodal irradiation is recommended in cases of histologically proven axillary involvement, while internal mammary node irradiation should be evaluated individually, based on the benefit/risk balance, particularly due to potential cardiac toxicity. Moderate hypofractionation is now the standard for whole-breast irradiation after lumpectomy, regardless of patient profile, due to its equivalent efficacy compared to conventional fractionation. It is also feasible for chest wall irradiation. Furthermore, recent randomized trials have shown that moderate hypofractionation can be applied to nodal irradiation without increased toxicity. For whole-breast irradiation alone, ultra hypofractionation (26<!--> <!-->Gy delivered in five fractions) has demonstrated non-inferiority to moderate hypofractionation. Target volume delineation for the breast with or without boost, chest wall, and nodal areas relies on clinical, surgical, pathological, and initial imaging data. Various techniques are available (three-dimensional conformal radiotherapy or intensity-modulated radiotherapy); the selected approach should optimize target coverage while respecting organ-at-risk constraints. Respiratory gating should be offered when it helps reduce exposure to organs at risk, particularly the heart. Adjuvant chemotherapy is generally not delivered concurrently with radiotherapy. Hormone therapy may be initiated before, during, or after irradiation.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104767"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncology","authors":"Charles Raynaud ,&nbsp;Stéphane Supiot ,&nbsp;Jennifer Le Guévelou ,&nbsp;Pierre Blanchard ,&nbsp;Jihane Boustani ,&nbsp;Maximilien Rogé ,&nbsp;Guilhem Roubaud ,&nbsp;Vincent Marchesi ,&nbsp;Igor Latorzeff ,&nbsp;Paul Sargos","doi":"10.1016/j.canrad.2025.104712","DOIUrl":"10.1016/j.canrad.2025.104712","url":null,"abstract":"<div><div>This article aims to report the recommendations from the French society for radiation oncology (Société française de radiothérapie oncologique, SFRO) on the use of external beam radiotherapy in the management of testicular cancer. Testicular cancers account for 1 % of adult neoplasms yet represent the most frequently diagnosed urological tumour in young men. Most of testicular cancers (95 %) are germ cell tumours, which include both seminomatous and non-seminomatous tumours. Surveillance is the preferred option for stage I seminoma following orchidectomy, but adjuvant chemotherapy or para-aortic radiotherapy remain possible options. For stages IIA/IIB seminoma, either chemotherapy or para-aortic and ipsilateral iliac nodal areas irradiation can be proposed. In non-seminomatous tumours, chemotherapy is the standard treatment. Target volumes, doses, fractionation regimens, and considerations for organs at risk are discussed. Follow-up recommendations are provided, aiming to ensure both early detection of cancer recurrence and late treatment-related side effects. These guidelines highlight the importance of a multidisciplinary approach for the management of germ cell tumours as well as careful consideration of long-term toxicities, in this young patient population with a long-life expectancy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104712"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of radiotherapy in the management of bladder cancer: Recommendations of the French Society for Radiation Oncology, 2025 update","authors":"Paul Sargos ,&nbsp;Louis-Marie Sauvage ,&nbsp;Jonathan Khalifa ,&nbsp;Olivier Riou ,&nbsp;David Azria ,&nbsp;Geneviève Loos ,&nbsp;Christophe Hennequin ,&nbsp;Vincent Marchesi ,&nbsp;Igor Latorzeff ,&nbsp;Stéphane Supiot","doi":"10.1016/j.canrad.2025.104715","DOIUrl":"10.1016/j.canrad.2025.104715","url":null,"abstract":"<div><div>We present the recommendations of the Société française de radiothérapie oncologie (SFRO; the French society for radiation oncology) regarding the indications and techniques for external beam radiotherapy for bladder cancer. Together with radical cystectomy, trimodal therapy for well-selected patients is one of the standard-of-care treatments in the management of localized muscle invasive bladder cancer, defined as a maximal trans-urethral resection of the bladder tumour, followed by radiotherapy and concomitant chemotherapy. Adjuvant radiotherapy is an option for patients with pathological high-risk bladder cancer. In the metastatic setting, consolidative radiotherapy is still under evaluation. Palliative radiotherapy using a hypofractionated regimen is a valid option in symptomatic patients.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104715"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines about radiotherapy and oncologic systemic treatments: Stop or continue?","authors":"Chloé Buchalet ,&nbsp;Constance Golfier ,&nbsp;Jean-Christophe Faivre ,&nbsp;David Azria ,&nbsp;Youlia Kirova ,&nbsp;Ariane Lapierre ,&nbsp;Igor Latorzeff ,&nbsp;Céline Mirjolet ,&nbsp;Christophe Hennequin ,&nbsp;Thomas Leroy ,&nbsp;Johann Marcel","doi":"10.1016/j.canrad.2025.104757","DOIUrl":"10.1016/j.canrad.2025.104757","url":null,"abstract":"<div><div>The combination of radiotherapy and oncologic systemic treatments has become clinical routine. We publish the first edition of the French guidelines to summarize the opportunities and risks of these combinations, aiming to harmonize standard practices. We first review the radiobiological principles underlying these associations. We also describe combinations known to be toxic and that should be avoided. Finally, we provide guidelines on the optimal timing for combining radiotherapy with chemotherapies, hormone therapies, targeted therapies and immunotherapy. These data are available on the website <span><span>https://www.radio-sync.com</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104757"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145314270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RecoRad™ 4th edition: The Société française de radiothérapie oncologique's “Recommendations” Commission-driven RecoRad™ 2025 updated version","authors":"Igor Latorzeff ,&nbsp;Stéphane Supiot","doi":"10.1016/j.canrad.2025.104762","DOIUrl":"10.1016/j.canrad.2025.104762","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104762"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of oropharyngeal squamous cell carcinoma: 2025 update","authors":"Vincent Grégoire ,&nbsp;Kévin Quintin ,&nbsp;Florence Huguet ,&nbsp;Pierre Boisselier ,&nbsp;Ulrike Schick ,&nbsp;Philippe Giraud ,&nbsp;Laure Vieillevigne ,&nbsp;Cyrus Chargari ,&nbsp;Thomas Leroy ,&nbsp;Yoann Pointreau ,&nbsp;Pierre Blanchard","doi":"10.1016/j.canrad.2025.104776","DOIUrl":"10.1016/j.canrad.2025.104776","url":null,"abstract":"<div><div>This article reviews the various exclusive or postoperative external radiotherapy and brachytherapy options for oropharyngeal squamous cell carcinoma. Dose levels, fractionation, and association with systemic treatments are presented. The need for neck node dissection following local treatment is discussed, as well as specificities for the management of p16-positive tumours. Guidelines for target volume selection and delineation are thoroughly elaborated.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104776"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensification or de-escalation? What is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?","authors":"Pierre Blanchard ,&nbsp;Anne Aupérin ,&nbsp;David Veyer ,&nbsp;Hélène Péré ,&nbsp;Michaël Chevrot ,&nbsp;Laure Monard ,&nbsp;Caroline Even ,&nbsp;Haitham Mirghani","doi":"10.1016/j.canrad.2025.104674","DOIUrl":"10.1016/j.canrad.2025.104674","url":null,"abstract":"<div><div>The incidence of human papillomavirus-related oropharyngeal cancers has been increasing steadily for several decades. They have a better prognosis than alcohol- and tobacco-related oropharyngeal cancers because they are more sensitive to radiotherapy and chemotherapy and patients have fewer comorbidities. However, some tumours have a high risk of recurrence, for which intensified therapy may be considered. On the other hand, for forms with a good prognosis, numerous therapeutic de-escalation strategies have been considered. The aim of this article is to review the standard of care in 2025, the various de-escalation strategies, the potential benefits of immunotherapy, and the impact of human papillomavirus on surveillance and screening of these cancers.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 5","pages":"Article 104674"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144662984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}